Yet despite knowing the genetic cause and some potential avenues for therapeutic intervention, the molecular pathogenesis of FKRP-related dystroglycanopathies and the metabolic response to gene replacement therapy have not been fully elucidated. This evidence concerns the gene FKRP and neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.